Detecting lung cancer through blood tests using DNA analysis
Official title: LUMEN-Dx: Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
Run by JaxBio Ltd · NCT06963307 · Data updated 2026-11-12
This study is testing a new blood test that looks for signs of lung cancer by analyzing DNA from dying cancer cells to see if it can help with early detection and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | JaxBio Ltd Industry-sponsored |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Ramat Gan) |
| Status | Recruiting |
| Started | May 2025 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | May 9, 2025 |
| Trial ID | NCT06963307 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 diagnosed with lung cancer, those with inconclusive lung imaging results, and healthy volunteers.
✕Probably not a fit
Patients with cancers other than lung cancer or those with active autoimmune diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify and characterize epigenetic signatures in cell-free DNA to develop a blood test for lung cancer detection. By analyzing DNA released from dying cancer cells, the study seeks to enhance existing diagnostic methods, predict treatment responses, and monitor minimal residual disease (MRD) in patients. Approximately 300 participants, including lung cancer patients and healthy controls, will be enrolled over a year and a half to evaluate the effectiveness of this approach in early diagnosis and treatment management.
Why it matters
Potential benefit: If successful, this study could lead to a non-invasive blood test that allows for early detection and better management of lung cancer.
How similar studies have gone: Other studies have shown promise in using liquid biopsies for cancer detection, suggesting potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women over 18 years old. * Patients diagnosed with lung cancer before systemic therapy. * Patients with inconclusive LDCT findings. * Healthy volunteers. * Patients with chronic lung diseases (COPD, pulmonary emphysema, acute pneumonia). Exclusion Criteria: * Subjects who did not sign a consent form. * Patients with cancer other than lung cancer. * Patients with HIV or hepatitis. * Patients with active autoimmune diseases (except lung-localized diseases). * Pregnant women or individuals unable to give informed consent.
Where it's running
-
Sheba Medical Center
Ramat Gan, Israel Recruiting
Study contacts
- Study coordinator: Yael Michaeli, Ph.D.
- Email: yaelmi@jaxbio.com
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations
This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.
-
Personalized exercise plan for cancer survivors
This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.
-
Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer
This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.
-
Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery
This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Phase II test of SKB571 for advanced non-small cell lung cancer
This study will test SKB571 given alone in adults with advanced non-small cell lung cancer to see if it is safe and can shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.